No records
|
525 |
Pasmanasari E.D., Pawitan J.A. |
57189246168;6508348067; |
The potential of electromyography signals as markers to detect and monitor Parkinson's disease |
2021 |
Biomedical and Pharmacology Journal |
14 |
1 |
|
373 |
378 |
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85104382880&doi=10.13005%2fbpj%2f2136&partnerID=40&md5=7df22fa914ed12da461baa35f3e9c2be |
Doctoral Program for Biomedical Sciences, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Histology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Stem Cell Medical Technology Integrated Service Unit, Dr. Cipto Mangunkusumo General Hospital, Faculty of Medicine, Universitas Indonesia, Indonesia; Stem Cell and Tissue Engineering Research Center, Indonesia Medical Education and Research Institute (IMERI), Faculty of Medicine Universitas Indonesia, Indonesia |
Pasmanasari, E.D., Doctoral Program for Biomedical Sciences, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Pawitan, J.A., Department of Histology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, Stem Cell Medical Technology Integrated Service Unit, Dr. Cipto Mangunkusumo General Hospital, Faculty of Medicine, Universitas Indonesia, Indonesia, Stem Cell and Tissue Engineering Research Center, Indonesia Medical Education and Research Institute (IMERI), Faculty of Medicine Universitas Indonesia, Indonesia |
Parkinson disease (PD) is a neurodegenerative disease that causes the loss of dopaminergic neurons in the brain. The imbalance in dopamine production causes motoric disorder that can produce specific electrical signal that can be detected by electromyography. Some methods were developed to diagnose PD and the use of a questionnaire and clinical observation was widely used to diagnose the disease. The limitation of the methods includes the fact that there are some differences in assessment results from clinicians due to the need of experience. The use of electromyography hopefully can obtain an objective assessment that can be easily used by clinicians. Some studies showed differences between normal muscle electric-activity compared to PD related abnormal muscle electric activity. Some methods were developed to use electromyography as a tool to diagnose PD related motoric symptoms, such as rigidity, gait abnormality and tremor. The use of electric signals, which are produce in muscle contraction, as markers to diagnose PD, as well as to monitor complications and the effect of therapy hopefully can be developed. In this review article, we will discuss about the use of electromyography signals that are related to PD. Therefore we will explain about basics of electromyography, the use of electromyography signals to detect tremor and gait abnormalities in PD, the use of electromyography for monitoring PD patients. © 2021 Oriental Scientific Publishing Company. All rights reserved. |
Dysphagia; Electromyography; Gait; Parkinson's disease; Tremor |
biological marker; Article; artificial neural network; dysphagia; electromyography; gait; human; nuclear magnetic resonance imaging; Parkinson disease; positron emission tomography; questionnaire; sensitivity and specificity; single photon emission computed tomography; transcranial Doppler ultrasonography; tremor |
Oriental Scientific Publishing Company |
09746242 |
|
|
Article |
Q4 |
191 |
19920 |
|
|
637 |
Tjoa K., Kusmardi K., Midoen Y.H. |
57222366705;56966625300;57197805109; |
Effects of Industrial Waste Fish Oil Administration on Interleukin-6 (Il-6) Expression at Mice Colon being Induced by Azoxymethane (AOM) and Dextran Sodium Sulphate (DSS) |
2021 |
Biomedical and Pharmacology Journal |
14 |
4 |
|
2227 |
2233 |
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85122824976&doi=10.13005%2fbpj%2f2321&partnerID=40&md5=bc79b4fdfe0aaabc3c89256150a440fb |
Faculty of Medicine, Universitas Indonesia, Jl Salemba Raya No 6, Senen, Jakarta, 10430, Indonesia; Departement of Anatomic Pathology, Faculty of Medicine, Universitas Indonesia, Jl Salemba Raya No 6, Senen, Jakarta, 10430, Indonesia; Drug Development Research Cluster, Indonesian Medical Education and Research Institute, Faculty of Medicine, Universitas Indonesia, Jl Salemba Raya No 6, Senen, Jakarta, 10430, Indonesia; Human Cancer Research Center, Indonesian Medical Education and Research Institute, Faculty of Medicine, Universitas Indonesia, Jl Salemba Raya No 6, Senen, Jakarta, 10430, Indonesia; Departement of Medical Biology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia |
Tjoa, K., Faculty of Medicine, Universitas Indonesia, Jl Salemba Raya No 6, Senen, Jakarta, 10430, Indonesia; Kusmardi, K., Departement of Anatomic Pathology, Faculty of Medicine, Universitas Indonesia, Jl Salemba Raya No 6, Senen, Jakarta, 10430, Indonesia, Drug Development Research Cluster, Indonesian Medical Education and Research Institute, Faculty of Medicine, Universitas Indonesia, Jl Salemba Raya No 6, Senen, Jakarta, 10430, Indonesia, Human Cancer Research Center, Indonesian Medical Education and Research Institute, Faculty of Medicine, Universitas Indonesia, Jl Salemba Raya No 6, Senen, Jakarta, 10430, Indonesia; Midoen, Y.H., Departement of Medical Biology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia |
Colorectal cancer (CRC) is the world's third most cancer and the second highest mortality rate. The searching for new anti-inflammation substances with less adverse effects than aspirin for chemoprevention and adjuvant chemotherapy of CRC is running. The most notable one is fish oil containing omega 3. Kusmardi, et al. studied that industrial waste fish oil omega-3 level comes close enough to conventional fish oil industry. Study aims to reducing the level IL-6 on mice colon tissue being induced CRC using AOM/DSS by fish oil administration. Thirty male Swiss Webster mice are grouped into six treatments: Positive control (aspirin), negative control (physiological saline), normal, high dose (fish oil 6mg/kgBW), medium dose (fish oil 3mg/kgBW), dan solvent control (corn oil). Colon tissue was stained using anti IL-6 antibody. Ten photos per slide were taken by microscope (400x), analyzed for the IL-6 expression by ImageJ®, and quantified for H-score. Data was analyzed using SPSS 24.0 (CI 95%) and p-value <0.05 is consider significant. Data are not normally distributed with median of 161.64 (119.4-260.67). Kruskal-Wallis test is significant in addition with Mann-Whitney test shows only high dose group has significant difference to negative control (p=0.008), medium dose (p=0.016) dan and solvent control (p=0.008). No significant difference reported between high dose and positive control group (p=0.69). High dose industrial waste fish oil can lower IL-6 expression in mice colon tissue induced CRC using AOM/DSS. © 2021 Oriental Scientific Publishing Company. |
Colitis Associated Cancer; Colorectal cancer; Interleukin-6; Omega-3 Fish Oil |
acetylsalicylic acid; CD34 antigen; cytochrome P450 2E1; fish oil; interleukin 6; microRNA; nonsteroid antiinflammatory agent; octamer transcription factor 4; probiotic agent; adjuvant chemotherapy; animal experiment; animal model; animal tissue; antiinflammatory activity; Article; azoxymethane-induced colon carcinogenesis; carcinogenesis; cardiovascular disease; cell proliferation; chemoprophylaxis; colon cancer; colon tissue; colorectal cancer; controlled study; dextran sulfate sodium-induced colitis; DNA methylation; drug megadose; fat intake; genomic instability; histone modification; immunohistochemistry; industrial waste; male; mortality rate; mouse; nonhuman; obesity; peritoneum adhesion; protein expression; quantitative analysis; rheumatoid arthritis; ulcerative colitis |
Oriental Scientific Publishing Company |
09746242 |
|
|
Article |
Q4 |
191 |
19920 |
|
|
No records
|
197 |
Permata T.B.M., Sato H., Gu W., Kakoti S., Uchihara Y., Yoshimatsu Y., Sato I., Kato R., Yamauchi M., Suzuki K., Oike T., Tsushima Y., Gondhowiardjo S., Ohno T., Yasuhara T., Shibata A. |
57197808751;55697961900;57211574572;57197814645;57221723636;57284438600;57285097100;57204087445;8307897300;57376271900;36453136000;57284002500;6508327402;35395665700;56562637100;8323572900; |
High linear energy transfer carbon-ion irradiation upregulates PD-L1 expression more significantly than X-rays in human osteosarcoma U2OS cells |
2021 |
Journal of Radiation Research |
62 |
5 |
|
773 |
781 |
|
2 |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85115918333&doi=10.1093%2fjrr%2frrab050&partnerID=40&md5=a1550b83230aa8ab90277d2716e9a556 |
Department of Radiation Oncology, Gunma University, Gunma, Maebashi, 371-8511, Japan; Department of Radiation Oncology, Faculty of Medicine Universitas Indonesia - Dr. Cipto Mangunkusumo Hospital, Jakarta, 10430, Indonesia; Gunma University Heavy IonMedical Center, Gunma, Maebashi, 371-8511, Japan; Gunma University Initiative for Advanced Research (GIAR), Gunma University, Gunma, Maebashi, 371-8511, Japan; Department of Diagnostic Radiology and Nuclear Medicine, Gunma University Graduate School OfMedicine, Gunma, Maebashi, 371-8511, Japan; Laboratory of Molecular Radiology, Center for Disease Biology and Integrative Medicine, Graduate School OfMedicine, The University OfTokyo, Bunkyo-ku, Tokyo, 113-8655, Japan; Department of Radiation Biology and Protection, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, 852-8523, Japan; Department of Radiation Medical Science, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, 852-8523, Japan |
Permata, T.B.M., Department of Radiation Oncology, Gunma University, Gunma, Maebashi, 371-8511, Japan, Department of Radiation Oncology, Faculty of Medicine Universitas Indonesia - Dr. Cipto Mangunkusumo Hospital, Jakarta, 10430, Indonesia; Sato, H., Department of Radiation Oncology, Gunma University, Gunma, Maebashi, 371-8511, Japan, Gunma University Heavy IonMedical Center, Gunma, Maebashi, 371-8511, Japan; Gu, W., Gunma University Initiative for Advanced Research (GIAR), Gunma University, Gunma, Maebashi, 371-8511, Japan, Department of Diagnostic Radiology and Nuclear Medicine, Gunma University Graduate School OfMedicine, Gunma, Maebashi, 371-8511, Japan; Kakoti, S., Department of Radiation Oncology, Gunma University, Gunma, Maebashi, 371-8511, Japan, Gunma University Initiative for Advanced Research (GIAR), Gunma University, Gunma, Maebashi, 371-8511, Japan; Uchihara, Y., Gunma University Initiative for Advanced Research (GIAR), Gunma University, Gunma, Maebashi, 371-8511, Japan; Yoshimatsu, Y., Gunma University Initiative for Advanced Research (GIAR), Gunma University, Gunma, Maebashi, 371-8511, Japan, Department of Diagnostic Radiology and Nuclear Medicine, Gunma University Graduate School OfMedicine, Gunma, Maebashi, 371-8511, Japan; Sato, I., Gunma University Initiative for Advanced Research (GIAR), Gunma University, Gunma, Maebashi, 371-8511, Japan; Kato, R., Laboratory of Molecular Radiology, Center for Disease Biology and Integrative Medicine, Graduate School OfMedicine, The University OfTokyo, Bunkyo-ku, Tokyo, 113-8655, Japan; Yamauchi, M., Department of Radiation Biology and Protection, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, 852-8523, Japan; Suzuki, K., Department of Radiation Medical Science, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, 852-8523, Japan; Oike, T., Department of Radiation Oncology, Gunma University, Gunma, Maebashi, 371-8511, Japan; Tsushima, Y., Gunma University Initiative for Advanced Research (GIAR), Gunma University, Gunma, Maebashi, 371-8511, Japan; Gondhowiardjo, S., Department of Radiation Oncology, Faculty of Medicine Universitas Indonesia - Dr. Cipto Mangunkusumo Hospital, Jakarta, 10430, Indonesia; Ohno, T., Department of Radiation Oncology, Gunma University, Gunma, Maebashi, 371-8511, Japan, Gunma University Heavy IonMedical Center, Gunma, Maebashi, 371-8511, Japan; Yasuhara, T., Laboratory of Molecular Radiology, Center for Disease Biology and Integrative Medicine, Graduate School OfMedicine, The University OfTokyo, Bunkyo-ku, Tokyo, 113-8655, Japan; Shibata, A., Gunma University Initiative for Advanced Research (GIAR), Gunma University, Gunma, Maebashi, 371-8511, Japan |
Programmed death ligand 1 (PD-L1) expression on the surface of cancer cells affects the efficacy of anti-PD-1/PD-L1 immune checkpoint therapy. However, the mechanism underlying PD-L1 expression in cancer cells is not fully understood, particularly after ionizing radiation (IR). Here, we examined the impact of high linear energy transfer (LET) carbon-ion irradiation on the expression of PD-L1 in human osteosarcoma U2OS cells. We found that the upregulation of PD-L1 expression after high LET carbon-ion irradiation was greater than that induced by X-rays at the same physical and relative biological effectiveness (RBE) dose, and that the upregulation of PD-L1 induced by high LET carbon-ion irradiation was predominantly dependent on ataxia telangiectasia and Rad3-related (ATR) kinase activity. Moreover, we showed that the downstream signaling, e.g. STAT1 phosphorylation and IRF1 expression, was upregulated to a greater extent after high LET carbon-ion irradiation than X-rays, and that IRF1 upregulation was also ATR dependent. Finally, to visualize PD-L1 molecules on the cell surface in 3D, we applied immunofluorescence-based super-resolution imaging. The three-dimensional structured illumination microscopy (3D-SIM) analyses revealed substantial increases in the number of presented PD-L1 molecules on the cell surface after high LET carbon-ion irradiation compared with X-ray irradiation. © 2021 The Author(s) 2021. Published by Oxford University Press on behalf of The Japanese Radiation Research Society and Japanese Society for Radiation Oncology. |
anti-PD-1/PD-L1 therapy; DNA damage response; high linear energy transfer (LET) carbon-ion therapy; PD-L1 expression |
Carbon; Cell membranes; Cytology; Diseases; Ionizing radiation; Ions; Molecules; Oncology; Radiotherapy; Anti-PD-1/programmed death ligand 1 therapy; Carbon ion therapy; Carbon ions; DNA damage response; High linear energy transfer carbon-ion therapy; High linear energy transfers; Human osteosarcoma; Ions irradiation; Programmed death ligand 1 expression; Up-regulation; Energy transfer; 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one; 3-amino-6-(4-(methylsulfonyl)phenyl)-N-phenylpyrazine-2-carboxamide; ATM protein; ATM protein, human; ATR protein, human; CD274 protein, human; interferon regulatory factor 1; IRF1 protein, human; messenger RNA; morpholine derivative; programmed death 1 ligand 1; pyrazine derivative; pyrone derivative; RNA; STAT1 protein; STAT1 protein, human; sulfone; tumor p |
Oxford University Press |
04493060 |
|
34196706 |
Article |
Q2 |
643 |
7838 |
|
|
236 |
Lancaster K.E., Mollan K.R., Hanscom B.S., Shook-Sa B.E., Ha T.V., Dumchev K., Djoerban Z., Rose S.M., Latkin C.A., Metzger D.S., Go V.F., Dvoriak S., Reifeis S.A., Piwowar-Manning E.M., Richardson P., Hudgens M.G., Hamilton E.L., Eshleman S.H., Susami H., Chu V.A., Djauzi S., Kiriazova T., Nhan D.T., Burns D.N., Miller W.C., Hoffman I.F. |
55503210000;26659057900;6603650318;55990940100;36988527800;8923601900;23472548200;12544917400;57235096800;35944632400;7102536801;57205192774;57193208279;35783326900;57203639655;6603567044;56450237600;7004740977;57202642757;57195576444;23495847800;55757875500;57317058700;7403171278;7406061778;7006682600; |
Engaging People Who Inject Drugs Living with HIV in Antiretroviral Treatment and Medication for Opioid Use Disorder: Extended Follow-up of HIV Prevention Trials Network (HPTN) 074 |
2021 |
Open Forum Infectious Diseases |
8 |
8 |
ofab281 |
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85118242331&doi=10.1093%2fofid%2fofab281&partnerID=40&md5=6133eea6e10cff9e76240789c9b5b783 |
Division of Epidemiology, College of Public Health, Ohio State University, 1841 Neil Ave, 334 Cunz Hall, Columbus, OH 43210-1351, United States; Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States; Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States; Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA, United States; UNC Vietnam, Hanoi, Viet Nam; Ukrainian Institute on Public Health Policy, Kyiv, Ukraine; Faculty of Medicine, University of Indonesia/Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Science Facilitation Department, FHI 360, Durham, NC, United States; Department of Health Policy and Management, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, United States; HIV Prevention Research Division, Department of Psychiatry, School of Medicine, University of Pennsylvania, Philadelphia, PA, United States; Academy of Labor, Social Relations and Tourism, Kyiv, Ukraine; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United States; Vietnam Administration of HIV/AIDS Control, Hanoi, Viet Nam; Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States; Division of Infectious Diseases, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States |
Lancaster, K.E., Division of Epidemiology, College of Public Health, Ohio State University, 1841 Neil Ave, 334 Cunz Hall, Columbus, OH 43210-1351, United States; Mollan, K.R., Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States; Hanscom, B.S., Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA, United States; Shook-Sa, B.E., Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States; Ha, T.V., Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States, UNC Vietnam, Hanoi, Viet Nam; Dumchev, K., Ukrainian Institute on Public Health Policy, Kyiv, Ukraine; Djoerban, Z., Faculty of Medicine, University of Indonesia/Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Rose, S.M., Science Facilitation Department, FHI 360, Durham, NC, United States; Latkin, C.A., Department of Health Policy and Management, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, United States; Metzger, D.S., HIV Prevention Research Division, Department of Psychiatry, School of Medicine, University of Pennsylvania, Philadelphia, PA, United States; Go, V.F., Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States; Dvoriak, S., Academy of Labor, Social Relations and Tourism, Kyiv, Ukraine; Reifeis, S.A., Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States; Piwowar-Manning, E.M., Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United States; Richardson, P., Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United States; Hudgens, M.G., Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States; Hamilton, E.L., Science Facilitation Department, FHI 360, Durham, NC, United States; Eshleman, S.H., Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United States; Susami, H., Faculty of Medicine, University of Indonesia/Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Chu, V.A., UNC Vietnam, Hanoi, Viet Nam; Djauzi, S., Faculty of Medicine, University of Indonesia/Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Kiriazova, T., Ukrainian Institute on Public Health Policy, Kyiv, Ukraine; Nhan, D.T., Vietnam Administration of HIV/AIDS Control, Hanoi, Viet Nam; Burns, D.N., Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States; Miller, W.C., Division of Epidemiology, College of Public Health, Ohio State University, 1841 Neil Ave, 334 Cunz Hall, Columbus, OH 43210-1351, United States; Hoffman, I.F., Division of Infectious Diseases, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States |
Background: People who inject drugs (PWID) living with HIV experience inadequate access to antiretroviral treatment (ART) and medication for opioid use disorders (MOUD). HPTN 074 showed that an integrated intervention increased ART use and viral suppression over 52 weeks. To examine durability of ART, MOUD, and HIV viral suppression, participants could re-enroll for an extended follow-up period, during which standard-of-care (SOC) participants in need of support were offered the intervention. Methods: Participants were recruited from Ukraine, Indonesia and Vietnam and randomly allocated 3:1 to SOC or intervention. Eligibility criteria included: HIV-positive; active injection drug use; 18-60 years of age; ≥1 HIV-uninfected injection partner; and viral load ≥1,000 copies/mL. Re-enrollment was offered to all available intervention and SOC arm participants, and SOC participants in need of support (off-ART or off-MOUD) were offered the intervention. Results: The intervention continuation group re-enrolled 89 participants, and from week 52 to 104, viral suppression (<40 copies/mL) declined from 41% to 29% (estimated 9.4% decrease per year, 95% CI-17.0%;-1.8%). The in need of support group re-enrolled 94 participants and had increased ART (re-enrollment: 55%, week 26: 69%) and MOUD (re-enrollment: 16%, week 26: 25%) use, and viral suppression (re-enrollment: 40%, week 26: 49%). Conclusions: Viral suppression declined in year 2 for those who initially received the HPTN 074 intervention and improved maintenance support is warranted. Viral suppression and MOUD increased among in need participants who received intervention during the study extension. Continued efforts are needed for widespread implementation of this scalable, integrated intervention. © 2021 The Author(s). |
antiretroviral therapy; HIV infection; injection drug use; methadone/therapeutic use; viral load |
antiretrovirus agent; buprenorphine; methadone; adult; Article; CD4 lymphocyte count; Consolidated Standards of Reporting Trial; controlled study; disease transmission; epidemic; evaluation and follow up; female; health care quality; health education; hepatitis C; human; Human immunodeficiency virus infection; incidence; injection drug user; integrated health care system; intervention study; interview; major clinical study; male; medication compliance; medication for opioid use disorder; medication for opioid use disorder; middle aged; opiate addiction; outcome assessment; paramedical personnel; practice guideline; psychosocial development; randomized controlled trial; telephone interview; viral suppression; virus load; World Health Organization; young adult |
Oxford University Press |
23288957 |
|
|
Article |
Q1 |
1546 |
2161 |
|
|
871 |
Turana Y., Widyantoro B., Situmorang T.D., Delliana J., Roesli R.M.A., Danny S.S., Suhardjono, Sofiatin Y., Hermiawaty E., Kuncoro A.S., Barack R., Beaney T., Ster A.C., Poulter N.R., Santoso A. |
56083326000;35286148600;57202120316;57208720930;26428909500;56221848700;57205723084;56815068100;57208721982;56008103000;57202111674;55614780900;57221978746;7006154423;36905206100; |
May measurement Month 2018: An analysis of blood pressure screening results from Indonesia |
2021 |
European Heart Journal, Supplement |
22 |
|
|
H66 |
H69 |
|
2 |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85101322980&doi=10.1093%2fEURHEARTJ%2fSUAA031&partnerID=40&md5=16a05b90991c40fdd180dd4e051eaaad |
Department of Neurology, School of Medicine and Health Science, Atma Jaya Catholic University of Indonesia, Jakarta, 14440, Indonesia; Department of Cardiology - Vascular Medicine, Faculty of Medicine, Universitas Indonesia, National Cardiovascular Center, Harapan Kita Hospital, Jl. S. Parman Kav 87, Slipi, Jakarta, 11420, Indonesia; Division of Nephrology, Department of Internal Medicine, PGI Cikini Hospital, Jakarta, 10330, Indonesia; Department of Cardiology, Directorate of Non-Communicable Disease, Ministry of Health - Republic of Indonesia, Jalan Percetakan Negara 29, Jakarta, 10560, Indonesia; Department of Internal Medicine, Faculty of Medicine, Padjadjaran University, Hasan Sadikin General Hospital, Bandung, 40161, Indonesia; Division of Nephrology and Hypertension, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia-Cipto, Mangunkusumo National General Hospital, Jalan Pangeran Diponegoro No: 71, Jakarta, 10430, Indonesia; Department of Public Health, Faculty of Medicine, Padjadjaran University, Jalan Prof. Eijkman 38, Bandung, 40161, Indonesia; Department of Neurology, National Cardiovascular Center, Harapan Kita Hospital, Jl. S. Parman Kav 87, Slipi, Jakarta, 11420, Indonesia; Department of Cardiology, MMC Hospital, Jakarta, Indonesia; Imperial Clinical Trials Unit, Imperial College London, Stadium House, 68 Wood Lane, Shepherd's Bush, London, W12 7RH, United Kingdom; Department of Primary Care and Public Health, Imperial College London, St Dunstan's Road, London, W6 8RP, United Kingdom |
Turana, Y., Department of Neurology, School of Medicine and Health Science, Atma Jaya Catholic University of Indonesia, Jakarta, 14440, Indonesia; Widyantoro, B., Department of Cardiology - Vascular Medicine, Faculty of Medicine, Universitas Indonesia, National Cardiovascular Center, Harapan Kita Hospital, Jl. S. Parman Kav 87, Slipi, Jakarta, 11420, Indonesia; Situmorang, T.D., Division of Nephrology, Department of Internal Medicine, PGI Cikini Hospital, Jakarta, 10330, Indonesia; Delliana, J., Department of Cardiology, Directorate of Non-Communicable Disease, Ministry of Health - Republic of Indonesia, Jalan Percetakan Negara 29, Jakarta, 10560, Indonesia; Roesli, R.M.A., Department of Internal Medicine, Faculty of Medicine, Padjadjaran University, Hasan Sadikin General Hospital, Bandung, 40161, Indonesia; Danny, S.S., Department of Cardiology - Vascular Medicine, Faculty of Medicine, Universitas Indonesia, National Cardiovascular Center, Harapan Kita Hospital, Jl. S. Parman Kav 87, Slipi, Jakarta, 11420, Indonesia; Suhardjono, Division of Nephrology and Hypertension, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia-Cipto, Mangunkusumo National General Hospital, Jalan Pangeran Diponegoro No: 71, Jakarta, 10430, Indonesia; Sofiatin, Y., Department of Public Health, Faculty of Medicine, Padjadjaran University, Jalan Prof. Eijkman 38, Bandung, 40161, Indonesia; Hermiawaty, E., Department of Neurology, National Cardiovascular Center, Harapan Kita Hospital, Jl. S. Parman Kav 87, Slipi, Jakarta, 11420, Indonesia; Kuncoro, A.S., Department of Cardiology - Vascular Medicine, Faculty of Medicine, Universitas Indonesia, National Cardiovascular Center, Harapan Kita Hospital, Jl. S. Parman Kav 87, Slipi, Jakarta, 11420, Indonesia; Barack, R., Department of Cardiology, MMC Hospital, Jakarta, Indonesia; Beaney, T., Imperial Clinical Trials Unit, Imperial College London, Stadium House, 68 Wood Lane, Shepherd's Bush, London, W12 7RH, United Kingdom, Department of Primary Care and Public Health, Imperial College London, St Dunstan's Road, London, W6 8RP, United Kingdom; Ster, A.C., Imperial Clinical Trials Unit, Imperial College London, Stadium House, 68 Wood Lane, Shepherd's Bush, London, W12 7RH, United Kingdom; Poulter, N.R., Imperial Clinical Trials Unit, Imperial College London, Stadium House, 68 Wood Lane, Shepherd's Bush, London, W12 7RH, United Kingdom; Santoso, A., Department of Cardiology - Vascular Medicine, Faculty of Medicine, Universitas Indonesia, National Cardiovascular Center, Harapan Kita Hospital, Jl. S. Parman Kav 87, Slipi, Jakarta, 11420, Indonesia |
Elevated blood pressure (BP) is a significant burden worldwide, leading to high cardiocerebro-reno-vascular morbidity and mortality. For the second year of the May Measurement Month (MMM) campaign in Indonesia in 2018, we recruited 174 sites in 31 out of 34 provinces in Indonesia and screened through convenience sampling in public areas and rural primary health centres. Hypertension was defined as systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg, or both, or on the basis of receiving antihypertensive medication. Blood pressure was measured three times followed the standard global MMM protocol, multiple imputation was used to estimate the mean of the 2nd and 3rd BP readings if these were not recorded. A total of 91 222 individuals were screened, and after multiple imputations, 27 331 (30.0%) had hypertension. Of individuals not receiving antihypertensive medication, 14 367 (18.4%) were hypertensive. Among the 47.4% of hypertensive individuals on antihypertensive medication, 10 106 (78.0%) had uncontrolled BP. MMM17 and MMM18 were still the most extensive standardized screening campaigns for BP measurement in Indonesia. Compared to the previous study, the proportion with uncontrolled BP on medication was significantly higher and provided the substantial challenges in managing hypertension in the rural community. © The Author(s) 2020. |
Blood pressure; Community; Control; Hypertension; Screening |
antihypertensive agent; adult; antihypertensive therapy; Article; blood pressure measurement; controlled study; cross-sectional study; female; human; hypertension; hypertensive patient; Indonesia; major clinical study; male; primary health care; priority journal; rural population |
Oxford University Press |
1520765X |
|
|
Article |
Q3 |
389 |
12388 |
|
|
925 |
Surja S.S., Adawiyah R., Houbraken J., Rozaliyani A., Sjam R., Yunihastuti E., Wahyuningsih R. |
57209258108;57208658742;12770401000;57203065912;23398458200;57221273925;6507268400; |
Talaromyces atroroseus in HIV and non-HIV patient: A first report from Indonesia |
2021 |
Medical Mycology |
58 |
4 |
|
560 |
563 |
|
3 |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85085715396&doi=10.1093%2fMMY%2fMYZ090&partnerID=40&md5=9fec23d3506804c0bc622f42e14314ff |
Master Program in Biomedical Sciences, Faculty of Medicine, Universitas Indonesia, Indonesia; Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Indonesia; Westerdijk Fungal Biodiversity Institute, Netherlands; Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Indonesia; Department of Parasitology, School of Medicine and Health Sciences, Universitas Katolik Indonesia, Atma Jaya, Indonesia; Department of Internal Medicine, Faculty of Medicine, Universitas Kristen Indonesia, Indonesia; Department of Parasitology, Faculty of Medicine, Universitas Kristen Indonesia, Indonesia; Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Indonesia |
Surja, S.S., Master Program in Biomedical Sciences, Faculty of Medicine, Universitas Indonesia, Indonesia, Department of Parasitology, School of Medicine and Health Sciences, Universitas Katolik Indonesia, Atma Jaya, Indonesia; Adawiyah, R., Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Indonesia; Houbraken, J., Westerdijk Fungal Biodiversity Institute, Netherlands; Rozaliyani, A., Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Indonesia; Sjam, R., Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Indonesia; Yunihastuti, E., Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Indonesia, Department of Internal Medicine, Faculty of Medicine, Universitas Kristen Indonesia, Indonesia; Wahyuningsih, R., Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Indonesia, Department of Parasitology, Faculty of Medicine, Universitas Kristen Indonesia, Indonesia, Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Indonesia |
We performed morphology, molecular study and antifungal susceptibility test on 10 Talaromyces sp. isolates: eight clinical isolates (human immunodeficiency virus (HIV) and non-HIV-patient) and two isolates from rats. All strains produced red soluble pigment and microscopically showed Penicillium-like structure in room temperature and yeast-like structure in 37â—¦C. Based on molecular analysis, nine isolates were identified as Talaromyces atroroseus (including the isolates from rats) and one as T. marneffei. Our susceptibility result of T. marneffei supports the use of amphotericin B, itraconazole for talaromycosis marneffei management. Talaromyces atroroseus showed variable MIC to echinocandin, azole derivatives, 5-flucytosine and amphotericin B. © The Author(s) 2019. |
BenA; Indonesia; ITS; Talaromyces atroroseus; Talaromyces marneffei |
amphotericin B; anidulafungin; caspofungin; echinocandin; fluconazole; flucytosine; itraconazole; micafungin; posaconazole; pyrrole derivative; voriconazole; antifungal agent; antifungal susceptibility; Article; fungus isolation; human; Human immunodeficiency virus infected patient; Indonesia; mycosis; nonhuman; room temperature; Talaromyces; Talaromyces atroroseus; Talaromyces marneffei; talaromycosis; animal; classification; drug effect; genetics; Human immunodeficiency virus infection; Indonesia; isolation and purification; microbial sensitivity test; microbiology; pigmentation; rat; Talaromyces; Animals; Antifungal Agents; HIV Infections; Humans; Indonesia; Microbial Sensitivity Tests; Mycoses; Pigmentation; Rats; Talaromyces |
Oxford University Press |
13693786 |
|
31504774 |
Article |
Q1 |
1004 |
4362 |
|
|